Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01884038|
Recruitment Status : Withdrawn
First Posted : June 21, 2013
Last Update Posted : June 21, 2013
|Condition or disease||Intervention/treatment||Phase|
|Liver Transplant||Drug: treprostinil sodium Drug: Placebo||Phase 2 Phase 3|
In vitro and in vivo research has consistently demonstrated an array of potential beneficial effects of prostanoids under both immune and non-immune circumstances relevant to liver allografts. (1-3) Recent reviews summarize the pharmacologic rationale and nonclinical and clinical experience supporting for the use of prostanoids, including prostacyclin and its analogs, in reducing early morbidity and mortality associated with liver transplantation. Prostaglandin-class drugs, including prostacyclin and its analogs, could represent an important advance toward the goal of reducing transplant related morbidity, mortality and associated costs by providing these benefits. Additionally, the reduction in serum creatinine and reduced need for post-operative dialysis observed in some studies has implications in protecting the kidneys from the nephrotoxic affects of the immunosuppressant agents, especially during the early post-operative period.
As a chemically stable analog of prostacyclin (PGI2), peri-operative intravenous administration of Remodulin is hypothesized to ameliorate or prevent reperfusion damage and thereby decrease hospitalization time and improve the clinical outcome of liver transplantation, compared to placebo control. Remodulin, as a prostanoid, is expected to facilitate restoration of the blood supply to the revascularized graft, and to provide the well-characterized protective effects of this class of compounds in liver transplant patients.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Single Center, Randomized, Double-Blind, Parallel Placebo-Controlled Study of the Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients|
|Study Start Date :||June 2008|
|Estimated Primary Completion Date :||June 2010|
|Estimated Study Completion Date :||June 2010|
Drug: treprostinil sodium
A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials.
The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative
|Placebo Comparator: 2||
- Duration of the initial hospitalization (days) following transplantation [ Time Frame: up to 180 days ]
- Area under the curve (AUC) of serum aspartate transaminase (AST) levels. [ Time Frame: 7 days ]The difference in serum AST as measured by AUC during the first seven days post-transplant will be compared between placebo and Remodulin treatment groups. AST is a serum transaminase marker of hepatic injury, and the AUC of AST levels represents the total magnitude of injury the liver experiences against time.
- Serum AST and alanine transaminase (ALT ) levels after transplant (Peak and Area Under the Curve [AUC]) [ Time Frame: 7 days ]
- Primary allograft nonfunction defined as patient death or retransplant within 30 days due to liver failure [ Time Frame: 30 days ]
- Graft survival [ Time Frame: 30 days, 90 days and 180 days ]
- Subject survival at [ Time Frame: Day 30, 90, and 180 ]
- Post-transplant renal function [ Time Frame: 30 days ]
- Duration of time spent in the intensive care unit (ICU; days) during the initial hospitalization. [ Time Frame: up to 180 days ]
- Intra-operative blood product usage [ Time Frame: 1 day ]
- Death from any cause [ Time Frame: 180 days ]
- Total costs for initial transplant hospitalization [ Time Frame: up to 180 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01884038
|United States, Pennsylvania|
|University of Pittsburgh Medical Center, Starzl Transplantation Institute|
|Pittsburgh, Pennsylvania, United States, 15213|
|Principal Investigator:||Amadeo Marcos, MD||University of Pittsburgh Medical Center|
|Principal Investigator:||Raman Venkataramanan, Ph.D, F.C.P.||University of Pittsburgh Medcial Center|